After 24 h brefeldin A was supplemented at a final concentration of 80 nM using ethanol vehicle as control.
HSP27 Secretion Is Insensitive to Brefeldin A Treatment.
Except the 5 h incubation of OVCAR-3 cells, brefeldin A treatment did not affect intracellular levels of HSP27 neither in OVCAR-3 cells (5h: 1.30 [+ or -] 0.20, P = 0.0048; 24 h: 0.97 [+ or -] 0.21, P = 0.7389; 48 h: 1.00 [+ or -] 0.19, P = 0.9567) (Figure 4(b)) nor in SK-OV-3 cells (5 h: 1.02 [+ or -] 0.08, P = 0.6342; 24 h: 1.09 [+ or -] 0.77, P = 0.7599; 48 h: 0.98 [+ or -] 0.26, P = 0.8327) (Figure 4(e)).
Therefore, HSP27 transport via the endoplasmic reticulum appears unlikely and thus, endoplasmic reticulum inhibition by brefeldin A as shown in this study failed to block the secretion of HSP27.
The block of IL-6 liberation in the presence of brefeldin A served as positive control and demonstrated an unexpected increase in IL-6 secretion after 24 h restricted to SK-OV3 cells (Figure 4(d)).
While IL-6 secretion was significantly blocked in the presence of the endoplasmic reticulum secretory pathway inhibitor brefeldin A, HSP27 expression and secretion were not affected.
Ikehara, "Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum," Journal of Biological Chemistry, vol.
De Clerck, "Evaluation of monensin and brefeldin a for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes," Cytometry, vol.
One of these promising anticancer drugs is Brefeldin A (BFA), a cyclic macrolide with a lactone ring.
The main goal of this research programme is to couple Brefeldin A (BFA) with Aphios' SuperFluids critical fluid nanosomes (SFS-CFN) technology for intravenous administration to achieve and maintain therapeutic plasma concentrations.